The human renin gene (REN) is a good candidate in studies aimed at unravelling the genetic basis of essential hypertension and stroke. We previously established that both a BglI and an MboI dimorphisms (located respectively in the first and ninth introns of the REN gene) were associated with essential hypertension in a population of hyperlipidaemic US subjects. In this association (retrospective case-control) study, we investigated the haplotype distribution of alleles defined by the combination of REN BglI and MboI dimorphic sites in 329 hyperlipidaemic US Caucasian subjects referred to UCSF Medical Center (140 hypertensives, 141 normotensives, and 48 hypertensive patients who had suffered a stroke). A statistically significant association
Introduction
Hypertension and stroke represent increasing major health care problems facing aging societies. Those are complex disorders with multifactorial etiologies in which gene-gene and gene-environment interactions play a major role (for reviews, see references [1] [2] [3] [4] [5] . The considerable task facing molecular geneticists is to identify the quantitative trait loci (QTL) that are involved in the pathogenesis of essential hypertension (EHT) and stroke. [1] [2] [3] [4] [5] [6] A number of candidate genes have been investigated by association, linkage and sib-pair linkage analyses. [6] [7] [8] These studies have led to mixed results as for putative involvements and roles of the concerned genes in the onset of the disorders. [1] [2] [3] [4] [5] [6] [7] [8] [9] Using retrospective, association studies of the case-control type, we have previously shown that that renin (REN) gene variants (or variants of a neighbouring gene that lies in the vicinity of REN on chromosome 1) that are in linkage disequilibrium with two genetic markers, a dimorphic BglI site in intron 1 and a dimorphic MboI site in intron 9 of the REN gene, could be implicated in determining an individual's genetic susceptibility to EHT in two independent populations. [10] [11] [12] We looked here for putative associations between haplotypes constructed by combining these two markers and direct clinical diagnosis of EHT and stroke, and probed whether these associations occur through the effects of classical risk factors related to lipid disorders.
Materials and methods

Subjects
The sample population included a total of 329 unrelated individuals (141 normotensives, 140 hypertensives, and 48 patients who had suffered a stroke) and is presented in Table 1 . All subjects were US Caucasian out-patients referred to the Lipid Clinic of the Cardiovascular Research Center of the University of California San Francisco (UCSF, USA) for investigation and management of dyslipidaemiae. They all presented with hypercholesterolemia and various types of lipid disorders. Whenever available from patient charts, blood pressure levels, determined while subjects were not on antihypertensive medications, were recorded. The study was done in accordance with international guidelines and all subjects gave their informed consent. Part of the sample population was constituted by combining two sample groups that we described before: we determined BglI genotypes on 110 subjects (55 normotensives, 55 hypertensives) who had been typed for MboI, 11 and MboI genotypes on 136 subjects (66 normotensives, 70 hypertensives) who had been recruited for a study on BglI; 12 35 individuals (20 normotensives, 15 hypertensives) had been part of both studies (and had thus been genotyped for both markers); the 48 stroke patients had not been part of either study.
Patients were classified as having EHT if they had systolic blood pressures above 140 mm Hg and diastolic blood pressures above 90 mm Hg on at least three separate occasions, had no clinical signs, symptoms and laboratory findings suggestive of secondary hypertension, and had positive family history of hypertension (as assessed by direct questioning of occurrence of hypertension in any close relative).
Normotensive subjects were individuals who had no personal history of hypertension (documented by individual medical records as resting systolic blood pressures below 140 mm Hg and diastolic blood pressures below 90 mm Hg on at least three separate occasions), and no family history of hypertension.
The cohort of 'stroke patients' included individuals who had suffered at least one episode of stroke, which was diagnosed on the basis of clinical findings. All stroke patients were hypertensive (Table 1) .
Clinical and laboratory variables that were taken into account were the following ( ]; systolic and diastolic blood pressures (SBP and DBP) in millimetre (mm) of mercury (Hg); total serum cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C), total serum triglyceride (TG), high density lipoprotein-triglyceride (HDL-TG), low density lipoprotein-triglyceride (LDL-TG), very low density lipoprotein-triglyceride (VLDL-TG), apolipoprotein AI (ApoAI), apolipoprotein Bcontaining LDL (ApoB-LDL) and apolipoprotein Bcontaining VLDL (ApoB-VLDL), all expressed in milli-moles per litre (mmol/L); and total cholesterol over total triglyceride levels ratio (TC/TG). Lipid and blood pressure levels were measured on patients while they were off-medication.
Seventeen of the hypertensives (non-stroke patients) and 10 normotensives had a diagnosis of type II diabetes mellitus (NIDDM); none of the stroke patients had NIDDM.
DNA analysis
DNA was extracted from 5 mL blood samples according to usual methods. BglI and MboI twoallele polymorphisms were detected and visualised using polymerase chain reaction (PCR)-based assays that have been described previously.
10,12
Data analyses
Raw data was coded, entered and processed in an IBM-PC compatible computer using the Statistical Packages for Social Sciences (SPSS®) version 7.5 for Windows® software package. 13 Frequency estimates (with associated standard errors [s.e.]) were determined by the method of gene counting, 14 and disequilibrium was calculated as the function of the difference between the observed and expected genotype frequencies. Estimation of departure from HardyWeinberg proportions (D A ) and tests of statistical significance were obtained for each of the two dimorphisms as reported elsewhere. 15 Linkage disequilibrium values (gametic di-allelic pairwise disequilibrium, D) for the pair of dimorphisms (BglI-MboI) was measured by calculating the deviation of the observed frequency of the haplotype from that expected from multiplication of the individual allele frequencies. 16, 17 In the case double heterozygotes (BglI(ϩ)/BglI(Ϫ) with MboI(ϩ)/MboI(Ϫ)), the haplotype phase was estimated by the maximum-likelihood procedure described by Hill. 14 The significance of the difference of D* ϭ D/D max from 0 (D max is the maximum possible disequilibrium for a given pair of allele frequencies) was calculated as 2 with 1 degree of freedom (df) using a method described elsewhere. 16, 17 Student's t-tests were used to ascertain the sig-nificance of differences between mean values of any two continuous variables; Mann-Whitney tests were used for non-parametric distributions. KruskalWallis one-way analysis of variance was employed for comparison of mean values between more than two groups and to determine the presence of significant differences between group means. Chisquared analyses were performed to test for differences in proportions of categorical variables between two or more groups. Differences in the distributions of haplotypes according to clinical phenotypes (normotensive versus hypertensives versus stroke patients) were assessed using 3 ϫ 2 tables of association and chi-squared procedures. Odds ratio values were determined directly from data stratified from the 3 ϫ 2 tables. For all analyses, statistical significance was considered at significance level (P) values less than 0.05.
Results
Dimorphic BglI and MboI sites have been reported in, respectively, the first and ninth introns of the REN gene. 10, 12 We used PCR-based assays that we have described before for visualisation of these twoallele polymorphisms.
10,12 Figure 1 shows the relative locations of these sites and the haplotype nomenclature used here. The (ϩ) sign refers to the allele on which the corresponding restriction site is present and (Ϫ) means absence of the dimorphic site.
The distributions of the frequencies of genotypes and alleles of BglI and MboI markers are displayed in Tables 2 and 3 , respectively. For both sites, genotype and alleles distributions were determined in the groups of normotensives, hypertensives, stroke patients, and in the overall sample population combining these three groups. D A values for both BglI and MboI sites are not statistically significantly dif- (Tables 2 and 3) among normotensives, hypertensives and in the combined group. They are, however, different from zero in the group of stroke patients (Tables 2 and 3) . Therefore, the distributions of genotypes for both markers occur in Hardy-Weinberg proportions in normotensives, hypertensives and in the combined group, and show deviation from Hardy-Weinberg proportions in the group of stroke patients. The frequencies of BglI(ϩ) alleles were 0.32 ± 0.03, 0.40 ± 0.03 and 0.41 ± 0.05 amongst normotensives, hypertensives, and stroke patients, respectively (Table 2) ; corresponding MboI(ϩ) allele frequencies were 0.24 ± 0.03, 0.36 ± 0.03, and 0.44 ± 0.05 (Table 3 ). Although the difference in the distribution of the three BglI genotypes according to clinical diagnosis of EHT did not reach statistical significance ( 2 ϭ 4.34, 2 df, P ϭ 0.114, see Table 2 ), the distribution difference between normotensives and stroke patients was significant ( 2 ϭ 10.14, 2 df, P ϭ 0.0063, see Table 2 ). Distribution differences of MboI genotypes in relation to EHT and stroke were both statistically significant (EHT: 2 ϭ 10.78, 2 df, P ϭ 0.0046; stroke:
2 ϭ 15.94, 2 df, P ϭ 0.0003, see Table 3 ). Compared with normotensives, there is a higher proportion of BglI(ϩ)/BglI(ϩ) and MboI(ϩ)/MboI(ϩ) genotypes amongst EHT and stroke groups (respectively, 17.9% and 27.1% vs. 9.9% for BglI, see Table 2 ; and 10.7% and 29.2% vs. 7.1% for MboI, see Table 3 ).
Linkage disequilibrium between the two sites was assessed by constructing haplotypes as described in 'Subjects and methods', and the distributions of haplotypes were investigated in the four groups (Table 4 ). Allele and haplotype frequencies displayed in Tables 2, 3 and 4 were used to calculate the pairwise linkage disequilibrium between the two markers. The disequilibrium parameters --maximum likelihood estimates of the disequilibrium coef- Table 5 . There is no significant departure from equilibrium, which points to lack of linkage disequilibrium between the two markers.
The distribution and frequencies of the four haplotypes were investigated according to clinical phenotypes of EHT and stroke. Results shown in Table 4 indicate statistically significant differences in haplotypes distributions among normotensives vs hypertensives ( 2 ϭ 33.62, 3 df, P ϭ 2 ϫ 10 Ϫ7 ), and among normotensives vs stroke patients ( 2 ϭ 42.46, 3 df, P Ͻ 10
Ϫ8
). 
The association of the (ϩ,ϩ) (BglI(ϩ)-MboI(ϩ)) haplotypes with increased risk to EHT and stroke (Table 4) is reflected by the values of retrospective odds ratios (OR). Indeed, the OR of (Ϫ,Ϫ) vs (ϩ,ϩ) haplotypes is 3.27 (95% CI: 1.68-6.42, Yates corrected P ϭ 0.0002) for EHT and 5.69 (95% CI: 2.60-12.51, Yates corrected P ϭ 10
Ϫ6
) in the case of stroke (Table 6) .
OR for (Ϫ,Ϫ) vs (ϩ,Ϫ) are not significantly different from 1.0 and OR for (Ϫ,Ϫ) vs (Ϫ,ϩ) are 3.38 (2.03-5.65, P ϭ 7 ϫ 10 Ϫ7 ) for EHT and 3.57 (1.82-7.00, P ϭ 8 ϫ 10 Ϫ5 ) for stroke . Thus, OR for (Ϫ,Ϫ) vs combination of (Ϫ,ϩ) and (ϩ,ϩ) is 3.35 (2.16-5.19, P Ͻ 10 Ϫ7 ) for EHT and 4.31 (2.45-7.59, P Ͻ 10 Ϫ7 ) for stroke (Table 6) .
We also evaluated putative associations of BglIMboI haplotypes with systolic and diastolic blood pressure levels, as well as with classical risk factors related to lipid, lipoprotein and apolipoprotein levels (Table 6 ). Statistically significant associations were detected with DBP, TC, HDL-C and LDL-C. To establish whether these detected associations were real, we applied multiple logistic regression analysis (MLR), taking BglI-MboI haplotypes as the dependent variable and all variables displayed in Table 6 as the independent variables. Statistical significance observed in the four above-mentioned cases was lost, and therefore the individual associations had been spurious.
Furthermore, there were no significant differences in the frequencies of BglI and MboI genotypes among NIDDM hypertensives and normotensive subjects (data not shown).
Discussion
The human REN gene plays a key role in the regulation of the RAAS system and has a demonstrated functional role in hypertensive and stroke-prone animal models. [1] [2] [3] [4] [5] [6] It is thus of particular appeal in investigations aimed at identifying QTLs implicated in EHT and allied clinical manifestations. So far, however, both positive associations with EHT, family history of EHT and intermediate phenotypes [10] [11] [12] [18] [19] [20] [21] [22] [23] and negative results as for association or linkage studies with EHT [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] have been reported.
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There are several different strategies that are being used for identifying QTLs that are involved in determining an individual's genetic susceptibility to complex disorders, and they all have their own limitations and pitfalls. [37] [38] [39] [40] Among these, association (retrospective of the case-control type) studies at candidate gene loci now represent a well-accepted method for attempting to uncover the molecular architecture of EHT and stroke. 6, 7, [37] [38] [39] [40] [41] Using a retrospective-case control design, we looked for associations between BglI-MboI haplotypes of the human REN gene and direct clinical diagnosis of EHT and stroke.
The sample population was composed of unrelated US Caucasian subjects who presented with hypercholesterolemia of mixed types, and who were discriminated according to hypertensive and stroke vs normotensive clinical phenotypes. Both hypertensives and stroke patients were marginally overweight and normotensives were in the upper range of the 'normal' category (Table 1 ). On average, stroke patients were older (Table 1) .
Individual allele frequencies of BglI and MboI markers among normotensives and hypertensives (Tables 2 and 3 ) are in very good agreement with the values that we reported previously for these two markers. 11, 12 When considered individually, and given the number of cases in this study, the MboI dimorphic site is significantly associated with EHT, which agrees with what we reported previously; 11 the association of BglI with EHT does not reach statistical significance. This contrasts with what we had observed before, 12 although the smaller number of cases in this study would account for the loss of significance. Both dimorphic sites, however, are strongly associated with direct clinical diagnosis of stroke (Tables 2 and 3 ). In fact, BglI and MboI allele proportions depart from Hardy-Weinberg equilibrium in the stroke group, which would be expected in the case of a group of patients in whom there is a strong, positive association with a clinical phenotype. Thus, in this investigation, MboI(ϩ) alleles are associated with EHT and stroke, and BglI(ϩ) alleles are associated with stroke.
BglI and MboI sites, although separated by less than 10 kb, appear to be in linkage equilibrium, so there is added value in constructing haplotypes combining these two sites. The association evidenced with both individual markers becomes indeed stronger when using BglI-MboI haplotypes, and their distributions are highly statistically different in EHT and stroke patients as compared with normotensives. On average, (Ϫ,ϩ) haplotypes indicate a 3.4-fold increased odds of presenting with EHT before or at age 55.7 year and a 3.6-fold odds of suffering from a stroke before or at 62.6 year. Corresponding odds associated with (ϩ,ϩ) haplotypes are 3.3 and 5.7, respectively, and odds associated with combined (Ϫ,ϩ) and (ϩ,ϩ) are 3.4 and 4.3. We have therefore evidenced that alleles determined by (Ϫ,ϩ) and (ϩ,ϩ) REN BglI/MboI haplotypes dis- criminate for direct clinical diagnoses of EHT and stroke in a US Caucasian population of patients presenting with hypercholesterolemia (Table 7) . Although the associations with both clinical entities are highly significant, the correlation with stroke status is even stronger than that with EHT. It would therefore be interesting in future works to look for more specific associations of REN markers with diferent types of stoke, e.g. cerebral infarction and bleeding.
As the BglI and MboI dimorphisms are located in introns, they are probably not causative mutations of the effect uncovered here. The (Ϫ,ϩ) and (ϩ,ϩ) haplotypes, however, occur in linkage disequilibrium with genetic variants of the REN gene (or of a nearby gene that is in linkage disequilibrium with it) that may be directly implicated in an increased individual's genetic susceptibility to both EHT and stroke. The search for such variants will be the next step of this line of investigation.
